Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 12 min ago
Peer-reviewedCC BY 4.0BBA Advances

The long non-coding RNA LINC01089 facilitates prostate cancer progression

  • Sandra Vega Neira1,2
  • Damu Tang1,2
  1. 1Department of Medicine, McMaster University, Hamilton, ON, L8S 4K1, Canada
  2. 2The Research Institute of St Joe’s Hamilton, St Joseph’s Hospital, Hamilton, ON, L8N 4A6, Canada
Read full textDOICite

Abstract

Background: Evidence suggests LINC01809 being involved in prostate cancer (PC). We studied LINC01089 functionality, the underlying mechanisms, and translational potential in PC.

Methods: Multiple PC cohorts (local, TCGA, and others) were utilized. Human (DU145 and LNCaP) and murine (TRAMP-C2) PC cells were used to investigate LINC01089-derived oncogenic potential in vitro and in vivo.

Results: LINC01089 upregulation occurred in PC, Gleason score 9–10 tumors and metastasis. LINC01089 stratified PC recurrence. Plasma collected from patients (n = 235) prior to treatment contained elevated LINC01089, which was further increased in higher Gleason PCs and modestly correlated with PSA score. LINC01089-positively correlated genes contained a 15-gene panel (Sig15) and were dominantly enriched in RNA splicing in multiple PC datasets, with three genes (DDX17, LUC7L3, and HNRNPH1/Overlap3) conserved. Overlap3 and Sig15 effectively stratified the recurrence risk of PC and poor prognosis across 9 other cancer types, and captured the tumors' RNA splicing property, a major mechanism contributing to androgen receptor (AR) variants. Ectopic LINC01089 enhanced DU145, LNCaP, and TRAMP-C2 PC cell proliferation, colony formation, and migration, and conferred LNCaP and TRAMP-C2 cell proliferation under androgen deprivation, along with AR upregulation in the nucleus. In C57BL/6 mice, TRAMP-C2 LINC01089 allografts grew faster and expressed increased nuclear AR, Ki67, and AKT activation. TRAMP-C2 LINC01089 allografts expressed higher levels of Overlap3 and some Sig15 genes.

Conclusion: LINC01089 facilitates PC. Overlap3 and Sig15 are novel prognostic biomarkers reflecting cancer-associated RNA splicing. Plasma LINC01089 displays PC diagnostic potential.

Related

  1. PADI2 facilitates progression and cisplatin resistance of epithelial ovarian cancer via m6A methylation
    Xinming Yin, Jiamin Zhou, Shijie Zhao +9
    iSciencePeer-reviewedCC BY-NC-ND 4.0Molecular biology & gene regulationCell biologyCell PressCrossref
  2. DUSP13 promotes prostate cancer progression by regulating the ERK1/2 pathway
    Translational andrology and urologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Pan-Cancer Analysis Identifies LUC7L2 as a Prognostic Biomarker and Potential Functional Regulator of Prostate Cancer Progression
    Jialin Yuan, Ping Zhan, Jun Liu +4
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. JARID2 promotes prostate cancer progression associated with TET3-mediated activation of the FAK/PI3K/AKT signaling pathway
    Jinrun Wang, Yang Liu, Yanze Li +3
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  5. Human bone marrow adipocytes drive prostate cancer bone metastasis progression via lipid-mediated induction of Angiopoietinlike 4
    Marine Hernandez, Sauyeun Shin, David Rengel +9
    HALPreprintPublisher termsFull text1 citedOncologyHAL

Cite

BibTeXRIS
BibTeX
@article{neira2026long,
  title = {{The long non-coding RNA LINC01089 facilitates prostate cancer progression}},
  author = {Sandra Vega Neira and Damu Tang},
  journal = {BBA Advances},
  year = {2026},
  month = oct,
  doi = {10.1016/j.bbadva.2026.100205},
  url = {https://doi.org/10.1016/j.bbadva.2026.100205},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - The long non-coding RNA LINC01089 facilitates prostate cancer progression
AU  - Sandra Vega Neira
AU  - Damu Tang
PY  - 2026
DA  - 2026/10/14
JO  - BBA Advances
DO  - 10.1016/j.bbadva.2026.100205
UR  - https://doi.org/10.1016/j.bbadva.2026.100205
AB  - Background: Evidence suggests LINC01809 being involved in prostate cancer (PC). We studied LINC01089 functionality, the underlying mechanisms, and translational potential in PC.  Methods: Multiple PC cohorts (local, TCGA, and others) were utilized. Human (DU145 and LNCaP) and murine (TRAMP-C2) PC cells were used to investigate LINC01089-derived oncogenic potential in vitro and in vivo.  Results: LINC01089 upregulation occurred in PC, Gleason score 9–10 tumors and metastasis. LINC01089 stratified PC recurrence. Plasma collected from patients (n = 235) prior to treatment contained elevated LINC01089, which was further increased in higher Gleason PCs and modestly correlated with PSA score. LINC01089-positively correlated genes contained a 15-gene panel (Sig15) and were dominantly enriched in RNA splicing in multiple PC datasets, with three genes (DDX17, LUC7L3, and HNRNPH1/Overlap3) conserved. Overlap3 and Sig15 effectively stratified the recurrence risk of PC and poor prognosis across 9 other cancer types, and captured the tumors' RNA splicing property, a major mechanism contributing to androgen receptor (AR) variants. Ectopic LINC01089 enhanced DU145, LNCaP, and TRAMP-C2 PC cell proliferation, colony formation, and migration, and conferred LNCaP and TRAMP-C2 cell proliferation under androgen deprivation, along with AR upregulation in the nucleus. In C57BL/6 mice, TRAMP-C2 LINC01089 allografts grew faster and expressed increased nuclear AR, Ki67, and AKT activation. TRAMP-C2 LINC01089 allografts expressed higher levels of Overlap3 and some Sig15 genes.  Conclusion: LINC01089 facilitates PC. Overlap3 and Sig15 are novel prognostic biomarkers reflecting cancer-associated RNA splicing. Plasma LINC01089 displays PC diagnostic potential.
SN  - 2667-1603
ER  -